Ascelia Pharma AB

Ascelia Pharma AB

SSTO:ACE
0.57
SEK
-0.03
(-4.33%)
-0.42EPS
105.76MMarket Cap
Feb 11Next Earn
Ascelia Pharma AB
STO:ACE
(Nasdaq Stockholm)

Recent

price

0.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.75
-1.5
-2.6
-2.64
-2.61
-3.24
-1.48
-0.67
-0.42
Basic EPS, GAAP
- -
-0.64
-1.22
-2.26
-2.45
-2.49
-3.76
-1.16
-0.64
-0.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.37
3.42
8.13
5.79
6.33
3.72
1.52
0.82
0.78
0.6
Book Value per Share
0.63
1.67
6.45
4.39
5.15
2.54
0.35
0.23
0.33
0.17
Tangible Book Value per Share
33
33
25
38
48
50
34
54
113
130
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-24
-37
-99
-126
-131
-109
-80
-76
-55
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
20
55
219
178
250
123
16
22
42
22
Working Capital
- -
- -
- -
1
1
- -
- -
- -
- -
- -
LT Debt
78
112
276
236
308
181
74
79
99
80
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-25.77
-19.15
-38.54
-46.3
-53.7
-85.65
-104.43
-85.48
-56.41
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
127
134
134
Market Capitalization
367
395
106

Working Capital

SEK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
39
43
33
Cash, Cash Equivalents & STI
34
38
28
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
10
11
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.51%
26%
Free Cash Flow
- -
1.8%
15.06%
Net Income, GAAP
- -
-3.28%
-4.72%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.49
-0.39
-0.42
-0.29
-1.48
2025
-0.23
-0.2
-0.13
-0.13
-0.67
2026
-0.13
-0.09
-0.08
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Ascelia Pharma AB (publ) (Nasdaq Stockholm: ACE) develops and commercializes novel drugs for orphan oncology indications, focusing on unmet needs in rare cancer conditions. The company offers Orviglance, a novel oral manganese-based contrast agent for magnetic resonance imaging to detect and visualize focal liver lesions including metastases and primary tumors in patients with impaired kidney function who cannot use gadolinium-based agents; and Oncoral, an oral irinotecan chemotherapy tablet designed for improved safety and patient outcomes in gastric cancer and other difficult-to-treat cancers, with potential orphan drug status in the US and Europe. Ascelia Pharma operates globally with emphasis on the US and European markets, maintains headquarters in Malmö, Sweden, and traces origins to 1999. Recent developments include positive Phase 3 SPARKLE trial results for Orviglance in 2024 confirming superior visualization of liver lesions versus unenhanced MRI, with FDA orphan drug designation and favorable meeting outcomes confirming plans for a New Drug Application submission in mid-2025; a fully subscribed SEK 105 million rights issue in Q3 2024 extending cash runway to late 2025; gross proceeds of SEK 43 million from warrant exercises in April 2025; and a directed share issue raising approximately SEK 30 million in September 2025. The company also reports preparation for Phase 2 trials of Oncoral following successful Phase 1 completion and acceptance of SPARKLE data abstracts at the 2025 European Society of Gastrointestinal and Abdominal Radiology meeting.